Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Prostatic Neoplasms 16Carcinoma, Renal Cell 14Neoplasm Metastasis 8Carcinoma, Non-Small-Cell Lung 7Carcinoma, Hepatocellular 7Neoplasms 6Carcinoma, Medullary 6Thyroid Neoplasms 5Melanoma 5Breast Neoplasms 5Ovarian Neoplasms 4Neuroendocrine Tumors 4Carcinoma, Transitional Cell 4Brain Neoplasms 4Thyroid Cancer, Papillary 3Small Cell Lung Carcinoma 3Sarcoma 3Pancreatic Neoplasms 3Lung Neoplasms 3Kidney Neoplasms 3Adenocarcinoma, Follicular 3Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Sarcoma, Ewing 2Recurrence 2Pheochromocytoma 2Paraganglioma 2Pain 2Osteosarcoma 2Multiple Myeloma 2

Interventions

Paclitaxel 5Carboplatin 3Taxes 2Specimen Handling 2Nivolumab 2Biopsy 2rucaparib 1rebastinib 1pembrolizumab 1olaparib 1durvalumab 1cediranib 1capivasertib 1cabozantinib 1Magnetic Resonance Spectroscopy 1LY-2157299 1Immunoglobulin G 1Ifosfamide 1Fluid Therapy 1Disulfides 1DCC-2036 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Carcinosarcoma × cabozantinib × Clear all
NCT03367741 2026-06-02

Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
82 enrolled 11 charts
GynecologicSarcoma

Carcinosarcoma, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡